1 Result(s)

Article

Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa

The novel anti-malarial cipargamin (KAE609) has potent, rapid activity against Plasmodium falciparum. Transient asymptomatic liver function test elevations were previously observed in cipargamin-treated subjects ...

Gilles Ndayisaba, Adoke Yeka, Kwaku Poku Asante, Martin P. Grobusch… in Malaria Journal (2021)